Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target
at www.tipranks.com (Mon, 3-Aug 6:15 AM)
Envudeucitinib Phase 3 Results Highlight Alumis’ Progress—Robust PASI 90/100 Outcomes and Strong Cash Position Underline Growth Potential
Market Chameleon (Fri, 15-May 10:38 AM)
